Patoderm, Prudoxin, Qualiquan, Quitaxon, Sagalon, Silenor, Sinepin, Sinequan, Sinquan, and Zonalon. It is also marketed as a combination drug with levomenthol under the brand name Doxure. Approvals The oral formulations of doxepin are -approved for the treatment of depression and sleep-maintenance insomnia, and its topical formulations are FDA-approved the short-term management for some itchy skin conditions. In Australia and the United Kingdom, the only licensed indications are in the treatment of major depression and pruritus in eczema. Research Antihistamine Cidoxepin is under development by Elorac, Inc. for the treatment of chronic urticaria (hives). As of 2017, it is in phase II clinical trials for this indication. The drug was also under investigation for the treatment of allergic rhinitis, atopic dermatitis, and contact dermatitis, but development for these indications was discontinued. Headache Doxepin was under development by Winston Pharmaceuticals in an intranasal formulation for the treatment of headache. As of August 2015, it was in phase II clinical trials for this indication. Neuropathic pain As of 2017, there was no good evidence that topical doxepin was useful to treat localized neuropathic pain. References External links Alpha-1 blockers Alpha-2 blockers Antihistamines CYP2D6 inhibitors D2 antagonists Dibenzoxepins Dimethylamino compounds Embryotoxicants Hypnotics Muscarinic antagonists Sedatives Serotonin receptor antagonists Serotonin–norepinephrine reuptake inhibitors Sodium channel blockers Tricyclic antidepressants Wikipedia medicine articles ready to translate